世界の経口血糖降下薬（OAD）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Oral Antidiabetic (OAD) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4299
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、92ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、経口血糖降下薬（OAD）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）、用途別市場規模（病院、診療所、糖尿病治療センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・経口血糖降下薬（OAD）治療の市場動向
・企業の競争状況、市場シェア
・経口血糖降下薬（OAD）治療の種類別市場規模（スルホニル尿素剤、ビグアニド、腸内α-グルコシダーゼ阻害剤、その他）
・経口血糖降下薬（OAD）治療の用途別市場規模（病院、診療所、糖尿病治療センター、その他）
・経口血糖降下薬（OAD）治療の北米市場規模2016-2027（アメリカ、カナダ）
・経口血糖降下薬（OAD）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・経口血糖降下薬（OAD）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・経口血糖降下薬（OAD）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・経口血糖降下薬（OAD）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Pfizer、Eli Lilly、Merck、Sanofi、AstraZeneca、Glenmark、Novartis、Boehringer Ingelheim、Novo Nordisk、Mannkind）
・結論

Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.
North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.

Market Analysis and Insights: Global Oral Antidiabetic (OAD) Treatment Market
The global Oral Antidiabetic (OAD) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oral Antidiabetic (OAD) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oral Antidiabetic (OAD) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oral Antidiabetic (OAD) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oral Antidiabetic (OAD) Treatment market.

Global Oral Antidiabetic (OAD) Treatment Scope and Market Size
Oral Antidiabetic (OAD) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oral Antidiabetic (OAD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others

Segment by Application
Hospital
Clinics
Diabetics Treatment Centres
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Eli Lilly
Merck
Sanofi
AstraZeneca
Glenmark
Novartis
Boehringer Ingelheim
Novo Nordisk

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Antidiabetic (OAD) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Sulphonylureas
1.2.3 Biguanides
1.2.4 Intestinal α-Glucosidase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Oral Antidiabetic (OAD) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Diabetics Treatment Centres
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Oral Antidiabetic (OAD) Treatment Market Perspective (2016-2027)
2.2 Oral Antidiabetic (OAD) Treatment Growth Trends by Regions
2.2.1 Oral Antidiabetic (OAD) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oral Antidiabetic (OAD) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Oral Antidiabetic (OAD) Treatment Industry Dynamic
2.3.1 Oral Antidiabetic (OAD) Treatment Market Trends
2.3.2 Oral Antidiabetic (OAD) Treatment Market Drivers
2.3.3 Oral Antidiabetic (OAD) Treatment Market Challenges
2.3.4 Oral Antidiabetic (OAD) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Oral Antidiabetic (OAD) Treatment Players by Revenue
3.1.1 Global Top Oral Antidiabetic (OAD) Treatment Players by Revenue (2016-2021)
3.1.2 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Oral Antidiabetic (OAD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oral Antidiabetic (OAD) Treatment Revenue
3.4 Global Oral Antidiabetic (OAD) Treatment Market Concentration Ratio
3.4.1 Global Oral Antidiabetic (OAD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Antidiabetic (OAD) Treatment Revenue in 2020
3.5 Oral Antidiabetic (OAD) Treatment Key Players Head office and Area Served
3.6 Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
3.7 Date of Enter into Oral Antidiabetic (OAD) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Oral Antidiabetic (OAD) Treatment Breakdown Data by Type
4.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Type (2022-2027)

5 Oral Antidiabetic (OAD) Treatment Breakdown Data by Application
5.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Oral Antidiabetic (OAD) Treatment Market Size (2016-2027)
6.2 North America Oral Antidiabetic (OAD) Treatment Market Size by Type
6.2.1 North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021)
6.2.2 North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027)
6.2.3 North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2027)
6.3 North America Oral Antidiabetic (OAD) Treatment Market Size by Application
6.3.1 North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021)
6.3.2 North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027)
6.3.3 North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2027)
6.4 North America Oral Antidiabetic (OAD) Treatment Market Size by Country
6.4.1 North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021)
6.4.2 North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Oral Antidiabetic (OAD) Treatment Market Size (2016-2027)
7.2 Europe Oral Antidiabetic (OAD) Treatment Market Size by Type
7.2.1 Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2027)
7.3 Europe Oral Antidiabetic (OAD) Treatment Market Size by Application
7.3.1 Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2027)
7.4 Europe Oral Antidiabetic (OAD) Treatment Market Size by Country
7.4.1 Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type
8.2.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application
8.3.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region
8.4.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size (2016-2027)
9.2 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type
9.2.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2027)
9.3 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application
9.3.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2027)
9.4 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country
9.4.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type
10.2.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application
10.3.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country
10.4.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Oral Antidiabetic (OAD) Treatment Introduction
11.1.4 Pfizer Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Introduction
11.2.4 Eli Lilly Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Oral Antidiabetic (OAD) Treatment Introduction
11.3.4 Merck Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Introduction
11.4.4 Sanofi Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Introduction
11.5.4 AstraZeneca Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Glenmark
11.6.1 Glenmark Company Details
11.6.2 Glenmark Business Overview
11.6.3 Glenmark Oral Antidiabetic (OAD) Treatment Introduction
11.6.4 Glenmark Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.6.5 Glenmark Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Oral Antidiabetic (OAD) Treatment Introduction
11.7.4 Novartis Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Details
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Introduction
11.8.4 Boehringer Ingelheim Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Details
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Introduction
11.9.4 Novo Nordisk Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.9.5 Novo Nordisk Recent Development
11.10 Mannkind
11.10.1 Mannkind Company Details
11.10.2 Mannkind Business Overview
11.10.3 Mannkind Oral Antidiabetic (OAD) Treatment Introduction
11.10.4 Mannkind Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
11.10.5 Mannkind Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Oral Antidiabetic (OAD) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Sulphonylureas
Table 3. Key Players of Biguanides
Table 4. Key Players of Intestinal α-Glucosidase Inhibitors
Table 5. Key Players of Others
Table 6. Global Oral Antidiabetic (OAD) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Oral Antidiabetic (OAD) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Oral Antidiabetic (OAD) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2016-2021)
Table 10. Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2022-2027)
Table 12. Oral Antidiabetic (OAD) Treatment Market Trends
Table 13. Oral Antidiabetic (OAD) Treatment Market Drivers
Table 14. Oral Antidiabetic (OAD) Treatment Market Challenges
Table 15. Oral Antidiabetic (OAD) Treatment Market Restraints
Table 16. Global Oral Antidiabetic (OAD) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Oral Antidiabetic (OAD) Treatment Market Share by Players (2016-2021)
Table 18. Global Top Oral Antidiabetic (OAD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2020)
Table 19. Ranking of Global Top Oral Antidiabetic (OAD) Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Oral Antidiabetic (OAD) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
Table 23. Date of Enter into Oral Antidiabetic (OAD) Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Oral Antidiabetic (OAD) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Company Details
Table 64. Pfizer Business Overview
Table 65. Pfizer Oral Antidiabetic (OAD) Treatment Product
Table 66. Pfizer Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. Eli Lilly Company Details
Table 69. Eli Lilly Business Overview
Table 70. Eli Lilly Oral Antidiabetic (OAD) Treatment Product
Table 71. Eli Lilly Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 72. Eli Lilly Recent Development
Table 73. Merck Company Details
Table 74. Merck Business Overview
Table 75. Merck Oral Antidiabetic (OAD) Treatment Product
Table 76. Merck Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 77. Merck Recent Development
Table 78. Sanofi Company Details
Table 79. Sanofi Business Overview
Table 80. Sanofi Oral Antidiabetic (OAD) Treatment Product
Table 81. Sanofi Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 82. Sanofi Recent Development
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Oral Antidiabetic (OAD) Treatment Product
Table 86. AstraZeneca Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Glenmark Company Details
Table 89. Glenmark Business Overview
Table 90. Glenmark Oral Antidiabetic (OAD) Treatment Product
Table 91. Glenmark Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 92. Glenmark Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis Oral Antidiabetic (OAD) Treatment Product
Table 96. Novartis Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Boehringer Ingelheim Company Details
Table 99. Boehringer Ingelheim Business Overview
Table 100. Boehringer Ingelheim Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 101. Boehringer Ingelheim Recent Development
Table 102. Novo Nordisk Company Details
Table 103. Novo Nordisk Business Overview
Table 104. Novo Nordisk Oral Antidiabetic (OAD) Treatment Product
Table 105. Novo Nordisk Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 106. Novo Nordisk Recent Development
Table 107. Mannkind Company Details
Table 108. Mannkind Business Overview
Table 109. Mannkind Oral Antidiabetic (OAD) Treatment Product
Table 110. Mannkind Revenue in Oral Antidiabetic (OAD) Treatment Business (2016-2021) & (US$ Million)
Table 111. Mannkind Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oral Antidiabetic (OAD) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Sulphonylureas Features
Figure 3. Biguanides Features
Figure 4. Intestinal α-Glucosidase Inhibitors Features
Figure 5. Others Features
Figure 6. Global Oral Antidiabetic (OAD) Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinics Case Studies
Figure 9. Diabetics Treatment Centres Case Studies
Figure 10. Others Case Studies
Figure 11. Oral Antidiabetic (OAD) Treatment Report Years Considered
Figure 12. Global Oral Antidiabetic (OAD) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Oral Antidiabetic (OAD) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Oral Antidiabetic (OAD) Treatment Market Share by Regions (2022-2027)
Figure 16. Global Oral Antidiabetic (OAD) Treatment Market Share by Players in 2020
Figure 17. Global Top Oral Antidiabetic (OAD) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Oral Antidiabetic (OAD) Treatment Revenue in 2020
Figure 19. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Oral Antidiabetic (OAD) Treatment Market Share by Type (2016-2027)
Figure 23. North America Oral Antidiabetic (OAD) Treatment Market Share by Application (2016-2027)
Figure 24. North America Oral Antidiabetic (OAD) Treatment Market Share by Country (2016-2027)
Figure 25. United States Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Oral Antidiabetic (OAD) Treatment Market Share by Type (2016-2027)
Figure 29. Europe Oral Antidiabetic (OAD) Treatment Market Share by Application (2016-2027)
Figure 30. Europe Oral Antidiabetic (OAD) Treatment Market Share by Country (2016-2027)
Figure 31. Germany Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Share by Region (2016-2027)
Figure 41. China Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Oral Antidiabetic (OAD) Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Oral Antidiabetic (OAD) Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Oral Antidiabetic (OAD) Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Oral Antidiabetic (OAD) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 61. Eli Lilly Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 63. Sanofi Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 65. Glenmark Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 68. Novo Nordisk Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 69. Mannkind Revenue Growth Rate in Oral Antidiabetic (OAD) Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の経口糖尿病治療薬市場 2021：企業別、地域別、種類・用途別

Global Oral Antidiabetic Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z10291 2021年4月 105Pages
当調査資料では、経口糖尿病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。経口糖尿病治療薬の種類別市場規模（スルホニル尿素剤、メグリチニド、α-グルコシダーゼ阻害剤）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロ...

世界の経口血糖降下薬・インスリン類似体市場 2021：企業別、地域別、種類・用途別

Global Oral Hypoglycemic Agents and Insulin Analogues Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z10300 2021年4月 102Pages
当調査資料では、経口血糖降下薬・インスリン類似体のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。経口血糖降下薬・インスリン類似体の種類別市場規模（インスリン分泌促進物質、α-グルコシダーゼ阻害剤、インスリン増感剤）、用途別市場規模（病院、ドラッグストア...

世界の再発性多形性膠芽腫（GBM）治療市場規模・現状・予測（2021年-2027年）

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4963 2021年4月 91Pages
QYResearch社発行の本調査資料では、再発性多形性膠芽腫（GBM）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、テモゾロミド、放射線増感剤、ニトロソウレア薬、放射線療法、化学療法）、用途別市場規模（病院、診療所、外来手術セン...

世界のオピオイド誘発性便秘（OIC）治療市場規模・現状・予測（2021年-2027年）

Global Opioid-Induced Constipation (OIC) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4281 2021年4月 96Pages
QYResearch社発行の本調査資料では、オピオイド誘発性便秘（OIC）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口、非経口（皮下注射））、用途別市場規模（ドラッグストア、独立型薬局、病院薬局）、主要地域別市場規模（北米、アメリカ...

世界の急性間欠性ポルフィリン症（AIP）治療市場規模・現状・予測（2021年-2027年）

Global Acute Intermittent Porphyria Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0060 2021年4月 92Pages
QYResearch社発行の本調査資料では、急性間欠性ポルフィリン症（AIP）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（350mg、313mg）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日...

世界の多嚢胞性卵巣症候群（PCOS）治療市場規模・現状・予測（2021年-2027年）

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4690 2021年4月 99Pages
QYResearch社発行の本調査資料では、多嚢胞性卵巣症候群（PCOS）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口避妊薬、抗アンドロゲン剤、インスリン増感剤、抗うつ剤、抗肥満剤、その他）、用途別市場規模（卵巣楔状切除術、腹腔鏡下...

世界のアデノシンデアミナーゼ欠損症（ADA）治療市場規模・現状・予測（2021年-2027年）

Global Adenosine Deaminase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0096 2021年4月 96Pages
QYResearch社発行の本調査資料では、アデノシンデアミナーゼ欠損症（ADA）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アダーゲン、レブコビ）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、...

世界の神経精神障害＆治療市場規模・現状・予測（2021年-2027年）

Global Neuropsychiatric Disorders and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4097 2021年4月 97Pages
QYResearch社発行の本調査資料では、神経精神障害＆治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、ショック治療、その他）、用途別市場規模（病院、診療所、研究センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア...

世界の神経性食欲不振症（AN）治療市場規模・現状・予測（2021年-2027年）

Global Anorexia Nervosa Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0355 2021年4月 94Pages
QYResearch社発行の本調査資料では、神経性食欲不振症（AN）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（心理療法、薬理療法、その他）、用途別市場規模（病院、クリニック、在宅医療、その他）、主要地域別市場規模（北米、アメリカ、ヨー...

世界の髄膜炎診断・治療市場規模・現状・予測（2021年-2027年）

Global Meningitis Diagnosis and Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3698 2021年4月 95Pages
QYResearch社発行の本調査資料では、髄膜炎診断・治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ウイルス性髄膜炎、細菌性髄膜炎、その他）、用途別市場規模（病院・クリニック、診断センター）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界の経口糖尿病治療薬市場 2021：企業別、地域別、種類・用途別 The Oral Antidiabetic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
世界の口腔がん治療市場規模・現状・予測（2021年-2027年） Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue growth located in the oral cavity. It may arise as a primary lesion originating in any of the tissues in the mouth, by metastasis from a distant site of origin, or by extension from a neighboring a…
世界の多嚢胞性卵巣症候群治療市場規模・現状・予測（2021年-2027年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…
世界の心房細動（SPAF）治療における脳卒中予防市場規模・現状・予測（2021年-2027年） Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above. Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death. Market Analysis and Ins…
世界の急性間欠性ポルフィリン症（AIP）治療市場規模・現状・予測（2021年-2027年） Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyr…